Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. raised their price target for Maze Therapeutics from $27.00 to $37.00, indicating a potential upside of 37.04% from the current stock price.
• Maze Therapeutics has received multiple positive ratings, with two analysts rating it as Strong Buy and a consensus rating of "Buy" with an average target price of $33.83.
• Directors and institutional investors have shown interest in Maze Therapeutics, with notable insider selling and several new stakes from organizations such as the New York State Common Retirement Fund and Legal & General Group Plc.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) had its price objective lifted by research analysts at JPMorgan Chase & Co. from $27.00 to $37.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 37.04% from the stock's current price.

MAZE has been the topic of several other research reports. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Maze Therapeutics in a report on Thursday, September 18th. BTIG Research raised their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a report on Friday, September 12th. Guggenheim increased their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, September 15th. Finally, Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $33.83.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $27.00 on Monday. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $28.37. The company's 50-day moving average price is $17.06 and its 200-day moving average price is $13.17.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Buying and Selling

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund acquired a new stake in shares of Maze Therapeutics in the first quarter worth $25,000. CWM LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth about $28,000. Corebridge Financial Inc. purchased a new position in Maze Therapeutics during the first quarter valued at approximately $48,000. Legal & General Group Plc lifted its holdings in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after acquiring an additional 3,371 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after purchasing an additional 3,774 shares in the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.